Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Mol Cancer. 2015 Jul 2:14:128. doi: 10.1186/s12943-015-0393-2.

Deborah J L Wong¹, Lidia Robert^{1

2}, Mohammad S Atefi¹, Amanda Lassen¹, Geetha Avarappatt^{1

3}, Michael Cerniglia¹, Earl Avramis¹, Jennifer Tsoi⁴, David Foulad¹, Thomas G Graeber⁴, Begonya Comin-Anduix^{5

6}, Ahmed Samatar⁷, Roger S Lo^{4

6

8}, Antoni Ribas^{9

10

11

12}

¹ Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), 11-934 Factor Building, Los Angeles, CA, USA.
² Universitat Autonoma de Barcelona, UAB, Barcelona, Spain.
³ University of Applied Sciences, Vienna, Austria.
⁴ Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA.
⁵ Department of Surgery, Division of Surgical-Oncology, UCLA, Los Angeles, CA, USA.
⁶ Jonsson Comprehensive Cancer Center at UCLA, 10833 Le Conte Avenue, Los Angeles, CA, 90095-1782, USA.
⁷ Discovery Oncology Merck Research Laboratories, Merck Research Laboratories, Boston, Massachusetts, USA.
⁸ Department of Medicine, Division of Dermatology, UCLA, Los Angeles, California, USA.
⁹ Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), 11-934 Factor Building, Los Angeles, CA, USA. [email protected].
¹⁰ Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA. [email protected].
¹¹ Department of Surgery, Division of Surgical-Oncology, UCLA, Los Angeles, CA, USA. [email protected].
¹² Jonsson Comprehensive Cancer Center at UCLA, 10833 Le Conte Avenue, Los Angeles, CA, 90095-1782, USA. [email protected].

No abstract available

Publication types